Using continuous glucose monitoring to predict outcomes in acute coronary syndrome

Predictive Value of Glycemic Parameters Measured With the Freestyle Libre Pro iQ During Acute Coronary Syndrome

This study is testing if continuous glucose monitoring can help doctors predict outcomes for patients with acute coronary syndrome by looking at their blood sugar levels.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 850 (estimated)
• Ages: 18 Years to 85 Years
• Sex: All
• Sponsor: University Hospital, Montpellier (other)
• Locations: 9 sites (Béziers and 8 other locations)
• Trial ID: NCT06014112 on ClinicalTrials.gov

What this trial studies

This study investigates the predictive value of glycemic parameters measured with the Freestyle Libre Pro iQ device in patients hospitalized for acute coronary syndrome (ACS). It focuses on understanding how glycemic variability and hyperglycemia can influence short- and long-term cardiovascular events. The study aims to enroll patients diagnosed with ACS in a cardiac intensive care unit and will analyze their glucose levels to identify potential prognostic indicators. By utilizing continuous glucose monitoring, the research seeks to improve risk stratification and management of ACS patients.

Who should consider this trial

Good fit: Ideal candidates for this study are patients diagnosed with acute coronary syndrome who are being treated in a cardiac intensive care unit.

Not a fit: Patients in cardiogenic or septic shock or those with severely impaired health may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the ability to predict major cardiovascular events in ACS patients, leading to better management and outcomes.

How similar studies have performed: Previous studies have indicated that continuous glucose monitoring can provide valuable prognostic information in similar patient populations, suggesting a promising approach.

Eligibility criteria

Inclusion Criteria:

* Patients with ACS managed in a cardiac intensive care unit (ICU). The diagnosis of ACS will be made in the presence of chest pain with ST-segment elevation on the ECG for STEMI or ST-segment change and/or a positive troponin cycle (values in accordance with the center's protocol) for NSTEMI.

Exclusion Criteria:

* Subjects in cardiogenic or septic shock
* Subjects with ACS initially managed in a non-investigating center
* Failure to obtain free, informed, written consent signed by the participant and investigator upon admission to the ICU
* Person participating in another research study with an ongoing exclusion period
* Subjects participating in a study that may have an impact on post ACS prognosis
* Person deprived of his or her rights, person under guardianship or curatorship
* Person deprived of liberty (by judicial or administrative decision)
* Persons whose physical and/or psychological health is severely impaired, which, in the opinion of the investigator, may affect the participant's compliance to the study
* Pregnant or breastfeeding women
* Person who is not affiliated to a social security system or who is a beneficiary of such a system.

Where this trial is running

Béziers and 8 other locations

• Hospital of Béziers — Béziers, France (RECRUITING)
• University Hospital of Bordeaux — Bordeaux, France (RECRUITING)
• University Hospital of Montpellier — Montpellier, France (RECRUITING)
• University Hospital of Nîmes — Nîmes, France (RECRUITING)
• AP-HP Lariboisière Hospital — Paris, France (RECRUITING)
• APHP - Hôpital Européen Georges Pompidou — Paris, France (RECRUITING)
• Hospital of Pau — Pau, France (RECRUITING)
• University Hospital of Toulouse — Toulouse, France (RECRUITING)
• Vannes Bretagne Atlantique Hospital — Vannes, France (RECRUITING)

Study contacts

• Study coordinator: Ariane SULTAN, Professor

Conditions: Acute Coronary Syndrome, Continuous Glucose Measurement, Glycemic Variability, Cardiovascular Event, acute coronary syndrome, continuous glucose measurement, glycemic variability, cardiovascular event